{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:16:18Z","timestamp":1793945778651,"version":"4.8.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1S10OD028504"],"award-info":[{"award-number":["1S10OD028504"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1S10OD025132"],"award-info":[{"award-number":["1S10OD025132"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM007280"],"award-info":[{"award-number":["T32GM007280"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["3R01CA218600-05S1"],"award-info":[{"award-number":["3R01CA218600-05S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA078207"],"award-info":[{"award-number":["T32CA078207"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","award":["T32GM007280"],"award-info":[{"award-number":["T32GM007280"]}],"id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","award":["3R01CA230854S1"],"award-info":[{"award-number":["3R01CA230854S1"]}],"id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","award":["1S10OD025132"],"award-info":[{"award-number":["1S10OD025132"]}],"id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","award":["1S10OD028504"],"award-info":[{"award-number":["1S10OD028504"]}],"id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejmech.2024.116154","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T14:23:34Z","timestamp":1706279014000},"page":"116154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2"],"prefix":"10.1016","volume":"267","author":[{"given":"Julia","family":"Velez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Su","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. \u00dcmit","family":"Kaniskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-3862","authenticated-orcid":false,"given":"Jian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116154_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116154_bib2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/nrm1761","article-title":"The diverse functions of histone lysine methylation","volume":"6","author":"Martin","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.116154_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116154_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"Bachmann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116154_bib5","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1084\/jem.20181276","article-title":"Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML","volume":"216","author":"Basheer","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2024.116154_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13045-017-0547-3","article-title":"The polycomb group protein EZH2 induces epithelial\u2013mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter","volume":"11","author":"Gan","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2024.116154_bib7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1535-7163.MCT-17-0437","article-title":"Histone methyltransferase EZH2: a therapeutic target for ovarian cancer","volume":"17","author":"Jones","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2024.116154_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah3543","article-title":"EZH2 drives and defines an epigenetic subclass of lung cancer","volume":"8","author":"Beltran","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2024.116154_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116154_bib10","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116154_bib11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.116154_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2024.116154_bib13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1021\/acs.chemrev.6b00801","article-title":"Inhibitors of protein methyltransferases and demethylases","volume":"118","author":"Kaniskan","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2024.116154_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41573-020-00108-x","article-title":"Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease","volume":"20","author":"Bhat","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116154_bib15","first-page":"156","article-title":"FDA approves an inhibitor of a novel \u2018epigenetic writer\u2019","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116154_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11384","article-title":"Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance","volume":"7","author":"Brooun","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116154_bib17","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood-2017-08-804344","article-title":"Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas","volume":"131","author":"Bisserier","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116154_bib18","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41388-018-0459-x","article-title":"miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer","volume":"38","author":"Sun","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2024.116154_bib19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.CAN-17-1327","article-title":"Tamoxifen resistance in breast cancer is regulated by the EZH2-er\u03b1-GREB1 transcriptional Axis","volume":"78","author":"Wu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116154_bib20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41556-022-00850-x","article-title":"EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis","volume":"24","author":"Wang","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.116154_bib21","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ajpath.2021.01.013","article-title":"Noncanonical functions of the polycomb group protein EZH2 in breast cancer","volume":"191","author":"Anwar","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2024.116154_bib22","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.116154_bib23","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and methylation-independent roles of EZH2 as a transcription activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2024.116154_bib24","doi-asserted-by":"crossref","first-page":"10929","DOI":"10.1093\/nar\/gkac861","article-title":"A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation","volume":"50","author":"Wang","year":"2022","journal-title":"Nucl. Acids Res."},{"key":"10.1016\/j.ejmech.2024.116154_bib25","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/nm.3968","article-title":"SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2","volume":"21","author":"Kim","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.116154_bib26","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41388-023-02618-5","article-title":"Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader","volume":"42","author":"Yu","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2024.116154_bib27","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1038\/s41388-020-1332-2","article-title":"EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair","volume":"39","author":"Koyen","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2024.116154_bib28","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116154_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116154_bib30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116154_bib31","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1039\/D3CS00100H","article-title":"Chemically induced degradation of epigenetic targets","volume":"52","author":"Kabir","year":"2023","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2024.116154_bib32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acsptsci.2c00100","article-title":"Targeting triple-negative breast cancer by a novel proteolysis targeting chimera degrader of enhancer of Zeste homolog 2","volume":"5","author":"Dale","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2024.116154_bib33","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","article-title":"Discovery of a first-in-class EZH2 selective degrader","volume":"16","author":"Ma","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116154_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2023.102356","article-title":"Recent advances in developing degraders & inhibitors of lysine methyltransferases","volume":"76","author":"Velez","year":"2023","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116154_bib35","doi-asserted-by":"crossref","first-page":"10167","DOI":"10.1021\/acs.jmedchem.1c00460","article-title":"Design, synthesis, and evaluation of VHL-based EZH2 degraders to enhance therapeutic activity against lymphoma","volume":"64","author":"Tu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116154_bib36","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1021\/acs.jmedchem.0c02234","article-title":"Design and synthesis of EZH2-based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116154_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114462","article-title":"Discovery of precision targeting EZH2 degraders for triple-negative breast cancer","volume":"238","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116154_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chembiol.2019.11.004","article-title":"EED-targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex","volume":"27","author":"Hsu","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116154_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.chembiol.2019.11.006","article-title":"Degradation of polycomb repressive complex 2 with an EED-targeted bivalent chemical degrader","volume":"27","author":"Potjewyd","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116154_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202205573","article-title":"Targeted degradation of PRC1 components, BMI1 and RING1B, via a novel protein complex degrader strategy","volume":"10","author":"Park","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2024.116154_bib41","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1021\/acs.jmedchem.2c00345","article-title":"Exploring degradation of mutant and wild-type epidermal growth factor receptors induced by proteolysis-targeting chimeras","volume":"65","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116154_bib42","doi-asserted-by":"crossref","first-page":"10897","DOI":"10.1021\/acs.jmedchem.9b01528","article-title":"Discovery of a first-in-class mitogen-activated protein kinase kinase 1\/2 degrader","volume":"62","author":"Wei","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116154_bib43","doi-asserted-by":"crossref","first-page":"18054","DOI":"10.1021\/acs.jmedchem.1c01476","article-title":"Design, synthesis, and evaluation of potent, selective, and bioavailable AKT kinase degraders","volume":"64","author":"Yu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116154_bib44","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nrm2236","article-title":"The third dimension bridges the gap between cell culture and live tissue","volume":"8","author":"Pampaloni","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.116154_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.00033","article-title":"Is it time to start transitioning from 2D to 3D cell culture?","volume":"7","author":"Jensen","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2024.116154_bib46","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/nprot.2013.125","article-title":"Three-dimensional cell culturing by magnetic levitation","volume":"8","author":"Haisler","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2024.116154_bib47","doi-asserted-by":"crossref","first-page":"45745","DOI":"10.18632\/oncotarget.9935","article-title":"The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance","volume":"7","author":"Breslin","year":"2016","journal-title":"Oncotarget"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424000345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424000345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:05:42Z","timestamp":1777529142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424000345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":47,"alternative-id":["S0223523424000345"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116154","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116154"}}